PPARG and breast cancer: However, combined treatment with these agents resulted in a slight but in significant increase in COX-2 and PGDS levels in PPARγ siRNA transfected MCF-7 (Figure 9(a)) and MDA-MB-231 (Figure 9(b)) breast cancer cells.